Literature DB >> 10754447

Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors.

T Griesbacher1.   

Abstract

The development of selective antagonists for bradykinin B(2) receptors has greatly advanced research on the role of the kallikrein-kinin system in acute pancreatitis. Kinins released during the course of the inflammatory injury are the major cause of the vascular symptoms, i.e. pancreatic oedema formation and its consequences, such as haemoconcentration, hypovolaemia and hypotension. Kinins are also involved in the accumulation of potentially cytotoxic factors in the pancreatic tissue. However, treatment with B(2) antagonists must begin prior to the formation of pancreatic oedema in order to inhibit or attenuate the vascular effects. Visceral pain as a possible target symptom for treatment with B(2) antagonists at later time points is suggested by the B(2) receptor-mediated activation of nociceptive afferents. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754447     DOI: 10.1159/000028355

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  10 in total

1.  Drug-induced acute pancreatitis.

Authors:  Tracie Kaurich
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

Review 2.  Drug-induced acute pancreatitis: a review.

Authors:  Mark R Jones; Oliver Morgan Hall; Adam M Kaye; Alan David Kaye
Journal:  Ochsner J       Date:  2015

3.  Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats.

Authors:  Mitsuhiro Hirata; Izumi Hayashi; Kuniko Yoshimura; Ken-ichiro Ishii; Kazui Soma; Takashi Ohwada; Akira Kakita; Masataka Majima
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  Proinflammatory characteristics of a nonpeptide bradykinin mimic, FR190997, in vivo.

Authors:  I Hayashi; K Ishihara; Y Kumagai; M Majima
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

5.  Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study.

Authors:  Julie Rouette; Hui Yin; Emily G McDonald; Alan Barkun; Laurent Azoulay
Journal:  Drug Saf       Date:  2021-10-29       Impact factor: 5.606

Review 6.  Pancreas and Adverse Drug Reactions: A Literature Review.

Authors:  Konrad Sosnowski; Piotr Nehring; Adam Przybyłkowski
Journal:  Drug Saf       Date:  2022-07-05       Impact factor: 5.228

7.  Analysis of risk factors related to gastrointestinal fistula in patients with severe acute pancreatitis: a retrospective study of 344 cases in a single Chinese center.

Authors:  Zhipeng Hua; Yongjie Su; Xuefeng Huang; Kang Zhang; Zhengyu Yin; Xiaoming Wang; Pingguo Liu
Journal:  BMC Gastroenterol       Date:  2017-02-14       Impact factor: 3.067

Review 8.  Ever-increasing diversity of drug-induced pancreatitis.

Authors:  Simcha Weissman; Muhammad Aziz; Ryan B Perumpail; Tej I Mehta; Rutwik Patel; James H Tabibian
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

9.  ACVIM consensus statement on pancreatitis in cats.

Authors:  Marnin A Forman; Joerg M Steiner; P Jane Armstrong; Melinda S Camus; Lorrie Gaschen; Steve L Hill; Caroline S Mansfield; Katja Steiger
Journal:  J Vet Intern Med       Date:  2021-02-15       Impact factor: 3.333

10.  Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.

Authors:  RuiJun Chen; Marc A Suchard; Harlan M Krumholz; Martijn J Schuemie; Steven Shea; Jon Duke; Nicole Pratt; Christian G Reich; David Madigan; Seng Chan You; Patrick B Ryan; George Hripcsak
Journal:  Hypertension       Date:  2021-07-26       Impact factor: 9.897

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.